TAK-Circulator Corporation
  • HOME
  • NEWS/プレスリリース
  • 事業内容
  • 特許一覧
  • お問い合わせ
  • English
    • About us
    • News
    • Drug development business
    • patents
    • Contact Us

News/Press Release

​Sep.06, 2022
Will exhibit at “JAPAN HEALTHCARE VENTURE SUMMIT 2022” on 12-14 October 2022.(Open Link) 
July.20, 2022
TAKC-02 Exploratory Clinical Study registered (jRCTs031220218). 
(The exploratory clinical study of the oligonucleotide drug for male patients with moderate asthma)
​Jan.11, 2022
Selected for the “Jury's Special Award” at the Japan Healthcare Venture Summit 2021 (JHVS2021), which is given to those who have a particularly high possibility of practical application and potential of seeds.
The exhibitor pitch was held by the Ministry of Health, Labor and Welfare on 13-15 October 2021.(Open Link. Japanese release only)
May.19, 2022
Completed the Phase I Clinical Study of TAKC-02 (NCT05018533)
Aug.17, 2021
Started enrollment of TAKC-02 Phase I Clinical Study (NCT05018533). ​
Aug.10, 2021
​
Exhibited at “JAPAN HEALTHCARE VENTURE SUMMIT 2021” on 13-15 October 2021.
​Mar.29,2021
Nippon Shokubai Co., Ltd. has released a press release regarding the Completion of GMP Manufacturing for Oligonucleotide API. (Open Link)​
Sep.10, 2019
​
TAK-Circulator Announces to Collaborate on Development of TAKC-02 and Expand a Capital Alliance with Nippon Shokubai Co .,ltd through Third Party Allotment(Open Link)
Aug.02, 2016
​
TAK-Circulator Announces to Form a Capital Alliance with Nippon Shokubai Co.,ltd. (Open Link)
個人情報保護方針
サイトのご利用について
お問い合わせ
TAK-Circulator Corporation All Rights Reserved. ​​
  • HOME
  • NEWS/プレスリリース
  • 事業内容
  • 特許一覧
  • お問い合わせ
  • English
    • About us
    • News
    • Drug development business
    • patents
    • Contact Us